SCHEMBL20894239

SCHEMBL20894239

O=C(O)c1ccc2c(c1)C(=O)NCC2

nearest known ligand 0.58

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PARP10 Q53GL7 10/20 0.58
PARP1 P09874 7/20 0.58
F7 P08709 1/20 0.58
F3 P13726 1/20 0.58
TDP2 O95551 1/20 0.58
PARP11 Q9NR21 6/20 0.51
PDPK1 O15530 1/20 0.51
CDK2 P24941 1/20 0.48
KDM4E B2RXH2 2/20 0.47
MAPT P10636 1/20 0.47
ALDH1A1 P00352 1/20 0.47
F11 P03951 1/20 0.47
KLKB1 P03952 1/20 0.47
SRD5A1 P18405 1/20 0.46
SRD5A2 P31213 1/20 0.46
MAPKAPK2 P49137 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29631237 1.00 PARP10 (0.58) PARP10PARP1F7F3TDP2
Isophthalic Acid SCHEMBL28032858 0.94 PARP10 (0.53) PARP10PARP1F7F3TDP2
SCHEMBL30337030 0.87 PARP11 (0.58) PARP10PARP1TDP2PARP11PDPK1
SCHEMBL1417726 0.87 PARP11 (0.58) PARP10PARP1TDP2PARP11PDPK1
SCHEMBL14395011 0.85 PARP10 (0.61) PARP10PARP1F7F3TDP2
SCHEMBL30420500 0.85 PARP10 (0.57) PARP10PARP1F7F3TDP2
SCHEMBL5879567 0.83 TDP2 (0.61) TDP2KDM4EMAPTALDH1A1F11
SCHEMBL14395236 0.81 PARP10 (0.56) PARP10PARP1F7F3PARP11
SCHEMBL12663981 0.81 PARP10 (0.56) PARP10PARP1F7F3TDP2
SCHEMBL8163134 0.81 PARP10 (0.59) PARP10PARP1F7F3TDP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109563094-B (hetero) aryl-substituted piperidinyl derivatives, process for their preparation and pharmaceutical compositions containing them 法国施维雅药厂 2022-03-18 CN disclosed
WO-2021255091-A1 1,3,4-OXADIAZOLES AND THEIR DERIVATIVES AS FUNGICIDES BAYER AKTIENGESELLSCHAFT (DE) 2021-12-23 WO disclosed
US-10654849-B2 (Hetero)aryl-substituted-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them LES LABORATOIRES SERVIER (FR) 2020-05-19 US disclosed
EP-3468971-B1 NEW (HETERO)ARYL-SUBSTITUTED-PIPERIDINYL DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SERVIER LAB (FR) 2020-02-19 EP disclosed
US-20190144449-A1 (HETERO)ARYL-SUBSTITUTED-PIPERIDINYL DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM LES LABORATOIRES SERVIER (FR) 2019-05-16 US disclosed
EP-3468971-A1 NEW (HETERO)ARYL-SUBSTITUTED-PIPERIDINYL DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM Les Laboratoires Servier (FR) 2019-04-17 EP disclosed
CN-109563094-A Acyclic derivatives, their preparation method and the pharmaceutical composition containing them that new (miscellaneous) aryl replaces 法国施维雅药厂 2019-04-02 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190144449-A1 (HETERO)ARYL-SUBSTITUTED-PIPERIDINYL DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM BAX, BCL2, CCNK PARP10 288/4885PARP1 115/4885F7 4249/4885
US-10654849-B2 (Hetero)aryl-substituted-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them BAX, BCL2, CCNK PARP10 288/4885PARP1 115/4885F7 4249/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.